19 results
424B3
PTPI
Petros Pharmaceuticals, Inc.
14 Jan 22
Prospectus supplement
5:18pm
or clinical trials, which could result in regulatory sanctions and cause serious harm to Petros’ reputation.
Additionally, Petros is subject to the risk … proprietary and confidential information, which could harm our business and reputation or cause us to incur increased expenses to address any
424B5
a8whfyd8q5xsifdm
23 Dec 21
Prospectus supplement for primary offering
5:01pm
424B5
x3x7h3eq5lutzjg tq2
1 Dec 21
Prospectus supplement for primary offering
5:10pm
424B5
f1kw k4s97
15 Oct 21
Prospectus supplement for primary offering
5:01pm
10-K
911 k2ib9bm
31 Mar 21
Annual report
4:30pm
S-3
9pxspoxd7qo f7
29 Jan 21
Shelf registration
4:48pm
8-K/A
EX-10.1
ym6 q5dtc864o
31 Dec 20
Metuchen’s Management’s Discussion and Analysis of Financial Condition and Results of Operations
5:00pm
424B3
mypq2 zzdx5m06p96
2 Nov 20
Prospectus supplement
12:00am
S-4/A
kkcxl6 6pkc
30 Sep 20
Registration of securities issued in business combination transactions (amended)
9:21am
S-4
450v8t8z5wf
24 Jul 20
Registration of securities issued in business combination transactions
12:00am
- Prev
- 1
- Next